January 5, 2017 / 9:16 PM / a year ago

BRIEF-Momenta and CSL announce deal

Jan 6 (Reuters) - Csl Ltd

* Momenta and CSL announce collaboration and license agreement to develop fc multimer programs, including m230, a selective immunomodulator of fc receptors

* Momenta Pharmaceuticals- will receive a $50 million upfront license fee from csl and is eligible to receive future milestone and royalty payments for m230

* Momenta Pharmaceutical - under terms of agreement, momenta will grant CSL an exclusive, worldwide license to momenta’s intellectual property relating to m230

* Momenta Pharmaceuticals - CSL, Momenta intend to enter into research collaboration to develop additional fc multimer proteins

* Momenta Pharmaceuticals - momenta has option to enter into an agreement to co-promote m230 and any other collaboration product in u.s.

* Momenta pharmaceuticals - will also be eligible for up to $550 million in contingent clinical, regulatory and commercialization milestone payments

* Momenta pharmaceuticals - momenta has option to elect a cost and profit sharing arrangement

* Momenta .- Momenta would fund proportion of global development and commercialization costs in exchange for share of u.s. Profits, milestones and royalties outside u.s. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below